A synergy of activity, stability, and inhibitor-interaction of HIV-1 protease mutants evolved under drug-pressure

在药物压力下,HIV-1蛋白酶突变体的活性、稳定性和抑制剂相互作用之间产生了协同作用。

阅读:3

Abstract

A clinically-relevant, drug-resistant mutant of HIV-1 protease (PR), termed Flap+((I54V)) and containing L10I, G48V, I54V and V82A mutations, is known to produce significant changes in the entropy and enthalpy balance of drug-PR interactions, compared to wild-type PR. A similar mutant, Flap+((I54A)) , which evolves from Flap+((I54V)) and contains the single change at residue 54 relative to Flap+((I54V)) , does not. Yet, how Flap+((I54A)) behaves in solution is not known. To understand the molecular basis of V54A evolution, we compared nuclear magnetic resonance (NMR) spectroscopy, fluorescence spectroscopy, isothermal titration calorimetry, and enzymatic assay data from four PR proteins: PR (pWT), Flap+((I54V)) , Flap+((I54A)) , and Flap+((I54)) , a control mutant that contains only L10I, G48V and V82A mutations. Our data consistently show that selection to the smaller side chain at residue 54, not only decreases inhibitor affinity, but also restores the catalytic activity.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。